ePosters only

ePoster Submission

Submission deadline: Wednesday, 21 August 2019

Please note that abstracts accepted as "ePosters only" will be displayed on terminals during the congress. However they will not be presented at a specific session. In addition all ePosters will be available on the ECTRIMS Online Library.

For your references please find below the ePoster numbers.

ePoster numbers

ePoster Number Abstract Title First Name Last Name
EP1444 Is the antibody titer really useful to verify the immunization of VZV Vaccine in MS patient treated with Fingolimod? Signoriello Elisabetta
EP1445 Contribution of spinal cord lesions in diagnosing multiple sclerosis according to the McDonald 2017 criteria in patients with clinically isolated syndrome María Díaz Sánchez
EP1446 Factors associated with time from symptom onset to definite MS diagnosis in a low prevalence country Simón Cárdenas-Robledo
EP1447 New consensus diagnosis criteria of Neurosarcoidosis: Application in a French cohort of 35 patients Clément Richard
EP1448 Acute inflammatory myelitis - a 10-year clinical review Joana Guimarães
EP1449 Clinical Features to Aid in the Diagnosis of Acute Flaccid Myelitis versus Transverse Myelitis Alfred Balasa
EP1450 MOG-IgG longitudinally extensive transverse myelitis in a patient with systemic lupus erythematosus Philippe Antoine Bilodeau
EP1451 Severe demyelinating brain lesions in a patient with systemic mastocytosis: multiple sclerosis or brain mastocytosis? Ysoline Beigneux
EP1452 Prevalence of anti-JC -virus among patients suffering from multiple sclerosis in Kazakhstan Aksholpan Sharapkhanova
EP1453 Anti-MOG antibodies and neurofilament light chain serum levels in tumefactive Multiple Sclerosis: A longitudinal case report Marianthi Breza
EP1454 Myelin oligodendrocyte glycoprotein antibody-associated disease in a multi-ethnic Canadian cohort Helen Margot Cross
EP1455 Epidemiological, clinical, paraclinical and therapeutic characteristics of multiple sclerosis in childhood Khaoula Jemai
EP1456 PANGAEA 2.0 EVOLUTION: state of the art multiple sclerosis patient management in daily clinical practice to identify key parameters for a more unified and early diagnosis of SPMS Ulf Schulze-Topphoff
EP1457 Disability and walking speed are associated with quality of life in not active progressive MS: A baseline analysis of the SPI2 study Bruce Cree
EP1458 Predictors of low quality of life at disease onset among a Peruvian sample of MS patients Darwin Vizcarra
EP1459 Disability trajectories in relapsing-remitting multiple sclerosis Tomas Uher
EP1460 Neuromyelitis optica spectrum disorder: is it the Aquaporin-4 autoantibodies (AQP-4 Ab) seropositive a different entity from AQP-4 negative patients? A Colombian perspective Mariana Gaviria
EP1461 Mediterranean Diet assessment in Relapsing Remitting Multiple Sclerosis: a preliminary cross-sectional study in Italy Riccardo Giossi
EP1462 Multiple sclerosis in Argentina: methodological and baseline data from the Argentinean MS Registry (RelevarEM) Juan Ignacio Rojas
EP1463 Assessment of the Public Health Impact of Multiple Sclerosis (MS) on the patient´s perception in Spain Ester Moral Torres
EP1464 Health related quality of life and perceived social support in French and Lebanese MS patients: a comparative study Michella Ibrahim
EP1465 Clinical profile of elderly patients with multiple sclerosis in Colombia Paola Andrea Ortiz Salas
EP1466 Influence of DMT exposure on relapse rates during pregnancy in patients with multiple sclerosis Sandra Raunegger
EP1467 Racial and ethnic differences in multiple sclerosis hospitalizations in the United States from 2010 to 2016 Tetine Sentell
EP1468 Fatigue and cognitive dysfunction in early multiple sclerosis: possible association with autonomic symptom burden? Arianna Sartori
EP1469 Understanding The Patient Perspective: Living with Multiple Sclerosis (MS) and Managing MS Symptoms Joanna White
EP1471 Dissociation between indicators of cognitive status and neurophysiological response in patients with MS Оlena Mialovytska
EP1472 Depression and multiple sclerosis: influence on cognitive performance Eva Fernandez-Diaz
EP1473 Occurrence of epilepsy in MS patients - a retrospective study of two specialized centers in Northern Germany Matthias Grothe
EP1474 Neuropsychological profile of relapsing remitting multiple sclerosis in Kerala, India, and correlation with lesion load Sruthi S Nair
EP1475 The MRI-risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0) - Assessment of MRI specific knowledge in people with multiple sclerosis and its association with emotions towards MRI Insa Schiffmann
EP1476 Neural correlates of cognitive-motor dual tasks in multiple sclerosis: an fNIRS study Ludovico Pedullà
EP1477 Gait performance in Timed 25 foot walk test and subjective perceived limitation of activities of daily living Klara Novotna
EP1478 CCAS vs SDMT as a screening tool for cognitive impairment in cerebellar MS patients Ines Gonzalez- Suárez
EP1479 Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies Bart Van Wijmeersch
EP1480 Reported Quality of Life in those on High Efficacy Compared to First Line Disease Modifying Therapies in a Community Cohort Tamela Stuchiner
EP1481 Construct validity and test-retest reliability of the Swedish version of the Acceptance of Chronic Health Conditions Scale Andreas Wallin
EP1482 Patients reported outcome measures from relapsing remitting people with Multiple Sclerosis on first line disease modifying therapies in a real world setting Simona Bonavita
EP1483 Impact of multiple sclerosis upon employment status of the patients Anna Pokryszko-Dragan
EP1484 Self-Management and Coping strategies in patients with Multiple Sclerosis; A Multicenter-prospective study HÜSNÜ Efendi
EP1485 Patient reported fatigue and disability in multiple sclerosis: it matters how you ask and when you ask Jared Srinivasan
EP1486 Cost-effectiveness review of prolonged release fampridine in managing walking impairment in a population with advanced multiple sclerosis Rachel Farrell
EP1487 Low contrast visual acuity and ganglion cell layer thickness are promising outcome biomarkers after first event of acute demyelinating optic neuritis Sylvia Klineova
EP1488 Left vs. right in optic neuritis: is there a more frequently affected eye? Yavor Yalachkov
EP1489 Eye movement abnormalities: marker of cognitive dysfunction in Multiple Sclerosis ? Saloua Mrabet
EP1490 The prevalence of autoimmune thyroid disease in patients newly diagnosed with multiple sclerosis Maryam Poursadeghfard
EP1491 Anxiety in Argentinian patients with multiple sclerosis: prevalence and associated factors Anibal Chertcoff
EP1492 Emergency medical care for multiple sclerosis in the Campania Region (South Italy) from 2015 to 2017 Marcello Moccia
EP1493 Impact of systemic comorbidities on grey matter atrophy in Multiple Sclerosis Ethel Ciampi
EP1494 Epilepsy and Multiple Sclerosis: A comorbidity in Argentinian cohort patients without progressive forms Guido David Vazquez
EP1495 Nano hesperetin: improve myelin repair and ameliorate glial activation of optic chiasm in lysolecithin-induced focal demyelination model Saeideh Baradaran
EP1496 Establishing the role of miR-150 in Multiple Sclerosis and experimental autoimmune encephalomyelitis Eliane Piket
EP1497 Anti-IL-6 receptor antibody prevents blood-brain barrier disruption in mice with experimental autoimmune encephalomyelitis (EAE) Kenichi Serizawa
EP1498 P2RX7 gene exonic variants in familial multiple sclerosis Paloma Montero-Escribano
EP1499 Sequencing of AQP1, AQP4 and MOG genes in Spanish population with neuromyelitis optica spectrum disorders (NMOSD) María Díaz Sánchez
EP1500 The role of CD44 in the development of inflammatory lesions in the central nervous system Maria-Sophia Stadler
EP1501 Fluorescence Lifetime Imaging as a Method for B-Cell-Classification in MS Lesions of the Human Brain Hanna Josephin Eisenberg
EP1502 Immunological Impact of Dietary Methionine Availability in Preclinical Models of Multiple Sclerosis Victoria Hannah Mamane
EP1503 Multiparametric immunophenotyping of whole blood in IFNβ1a-treated multiple sclerosis patients Priyanka Devi-Marulkar
EP1504 The influence of catecholamines on Th17-immune response in multiple sclerosis Mikhail Melnikov
EP1505 BK Virus Can Be Neurotropic: A Rare Cause of PML Cansu Ayvacıoğlu
EP1506 The role of diet related short chain fatty acids in multiple sclerosis. A pilot study Laura Moles Alegre
EP1507 A higher intake of antioxidant from diet is associated with decreased odds of NMO-IgG seropositivity in neuromyelitis optica spectrum disorder patients Nasim Rezaeimanesh
EP1508 Cerebrospinal fluid markers in patients with multiple sclerosis Katerina Bucilova
EP1509 Early cognitive dysfunction as a marker of unfavorable course оf multiple sclerosis: prospective 12 years' study Dmitry Kasatkin
EP1510 Early cognitive impairment in multiple sclerosis patients in relation to brain atrophy, Egyptian sample Alaa Mohamed Abou-Steit
EP1511 Magnetic Resonance Spectroscopy: Correlates with DTI and Brain Atrophy in Multiple Sclerosis Kain Kyle
EP1512 Macrophage failure to reach a pro regenerative state reflects multiple sclerosis severity Jennifer Fransson
EP1513 Vitamin D - an effective antioxidant in an animal model of progressive Multiple Sclerosis? Sonja Hochmeister
EP1514 Neurotrophic factors are required for neuronal regeneration induced by interleukin-10 Sarah Hirschberg
EP1515 The importance of MRI pulse sequence selection in detecting brain hypointense lesions in multiple sclerosis. Relevance for the definition of “black holes” Caterina Lapucci
EP1516 A Statistical Reference Percentile Chart for Evaluating Brain Atrophy in Multiple Sclerosis Amir Mazhari
EP1517 Lateral ventricle volume change in Multiple Sclerosis: A preliminary study of brain atrophy using clinical routine MRI Shmuel Miron
EP1518 Lesion volume and spatial mapping performance of automatic lesion segmentation by volBrain and Lesion growth algorithm in multiple sclerosis Lin Zhao
EP1519 Preserved regional cortical volumes in multiple sclerosis patients with minimal disability compared to healthy volunteers Michaela Andelova
EP1520 Microglial activation in the normal appearing white matter predicts later disease progression in multiple sclerosis Marcus Sucksdorff
EP1521 Fully automated lesion segmentation using heavily trained 3D convolutional neural networks are equivalent to manual expert segmentations Julia Krüger
EP1522 Regional Corpus Callosum Cross-sectional Area Atrophy In Multiple Sclerosis Mikolaj Pawlak
EP1523 Volbrain: A useful brain segmentation software in Multiple Sclerosis Fernando Cortés-Enríquez
EP1524 Snickers or Mars? A functional magnetic resonance imaging task on preference-based decision making in multiple sclerosis Insa Schiffmann
EP1525 MRI of the optic nerve: Different characteristics of optic neuritis and optic nerve sheath meningioma Achim Gass
EP1526 Optical Coherence Tomography in Multiple Sclerosis and Neuromyelitis-Optica Doaa Abdellatif
EP1527 Peripapillary RNFL and macular volume measured with optical coherence tomography as possible biomarkers of ineffective disease activity control in very early RRMS patients Silvia Miante
EP1528 The beneficial effects of higher vitamin B6 intake in cognitive function improvement among patients with neuromyelitis optica spectrum disorder Nasim Rezaeimanesh
EP1529 Effect of Teriflunomide versus Dimethyl Fumarate on cognitive performance in multiple sclerosis patients: Real-world data Daniela Noa Zohar
EP1530 Cognitive assessment and cytokine profile of multiple sclerosis patients presenting with only optic neuritis and myelitis Erdem Tüzün
EP1531 Lipid-specific oligoclonal IgM bands and cognition in the early stages of multiple sclerosis Clàudia Coll Martinez
EP1532 Longitudinal pilot study to evaluate the effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis Anna Gil-S
EP1533 Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis Matilde Inglese
EP1534 Cannabinoid receptors in multiple sclerosis: genetic association and gene expression in immune cells Michael Hecker
EP1535 Serum glutamate and nitric oxide as markers of activity and relapses in multiple sclerosis Amr Mohamed Fouad
EP1536 Isotope dilution ultra-high performance liquid chromatography/tandem mass spectrometry quantitative analysis of kynurenine pathway intermediates as potential biomarkers for multiple sclerosis in human serum and cerebrospinal fluid Eva Hényková
EP1537 Using serum metabolomics to predict development of neutralising anti-drug antibodies in multiple sclerosis patients treated with IFNβ Kirsty Waddington
EP1538 Th1-like Th17 cells as potential early biomarker of treatment response to Dimethyl Fumarate Silvia Presas-Rodríguez
EP1539 Evidence of the Utility of CSF Neurofilament Light Chain Measurements in people with MS in Clinical Practice Saúl Reyes
EP1540 Study of exosomes derived from activated platelets in Multiple Sclerosis relapse and remission paired patients Jezabel Varadé
EP1541 Axonal damage of optic nerve correlates with physical and cognitive disability in multiple sclerosis Simona Petrescu
EP1542 Association of kappa-free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis Franziska Bachhuber
EP1543 High neurofilament light chain and high quinolinic acid levels in the CSF of patients with multiple sclerosis are independent predictors of active, disabling disease Cecilia Rajda
EP1544 PANGAEA 2.0: effectiveness of fingolimod in patients with disease activity switching from other DMTs and different treatment frequencies Ulf Schulze-Topphoff
EP1545 Fingolimod can suppress multiple sclerosis relapses without decreasing serum chemokine levels: implications for relapses after fingolimod discontinuation Yusei Miyazaki
EP1546 RAM-589.555 decreases CNS-infiltrating immune cells and favors their anti-inflammatory cytokine profile in acute relapse EAE affected mice Rina Zilkha-Falb
EP1547 Characteristics of multiple sclerosis patients treated with highly effective DMTs in a large real-world cohort Carrie Hersh
EP1548 Case Series: Central Nervous System Demyelination in the Setting of Tumor Necrosis Factor-α (TNF- α) Blockers: Uncommon Presentations and Therapeutic Strategies Sharon Stoll
EP1549 Efficacy and safety of teriflunomide in patients switching from other DMTs in the real-world TAURUS-MS I study Thorsten Rosenkranz
EP1550 Post-hoc Analysis to Evaluate the Effects of Subcutaneous Interferon β-1a in Subgroups of Patients from the PRISMS Study with Early Onset vs Late Onset Disease M.S. Freedman
EP1551 Assessment of differential effects of ENX-201 versus placebo, free methylprednisolone and/or non-targeted liposomes in healthy rats Pieter Jaap Gaillard
EP1552 Glatiramer Acetate Depot (extended-release) Accumulated Safety Data in Relapsing Remitting Multiple Sclerosis & Primary Progressive Multiple Sclerosis phase IIa studies Arnon Karni
EP1553 Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Safety and Efficacy Results From the Phase 3 EVOLVE-MS-1 Study Florian Then Bergh
EP1554 Rituximab treatment of multiple sclerosis in the Hospital District of Southwest Finland Marjo Nylund
EP1555 20-week results of the phase 3, multicenter, double-blind, placebo-controlled study of the original pegylated interferon beta-1a drug in patients with remitting multiple sclerosis Arina Zinkina-Orikhan
EP1556 Non-interventional, prospective study CLADQoL (CLADribine Tablets - evaluation of Quality of Life), data extraction March 2019 Iris-Katharina Penner
EP1557 Real world Efficacy and Safety Profile of Ocrelizumab therapy in patients with Multiple Sclerosis Vince Tran
EP1558 Peginterferon beta-1a every 2 weeks demonstrates better clinical outcomes than glatiramer acetate 40 mg/mL 3 times a week in patients with relapsing-remitting multiple sclerosis using a matching-adjusted indirect comparison of phase 3 trials Thomas Scott
EP1559 Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany - CONFIDENCE Baseline Characteristics Petra Dirks
EP1560 Regulation of the IFNß activity in MS patients via alternative splicing: soluble isoform of IFNß receptor Begoña Oliver-Martos
EP1561 Multiple Sclerosis Patients Initiating Dimethyl Fumarate Versus Fingolimod in the Real-World Setting Have Baseline Characteristics Associated with Worse Clinical Prognosis Carrie Hersh
EP1562 Concurrent autoimmune hemolytic anemia and multiple sclerosis relapse in the presence of aquaporin-1 antibodies, following treatment with Alemtuzumab John Tzartos
EP1563 Alemtuzumab as alternative to patients with relapsing-remitting multiple sclerosis who failed to Fingolimod Ana Mª López Real
EP1564 Human chorionic gonadotrophin: the potential link between pregnancy improvement in the context of Multiple Sclerosis Lorena Vanesa Juriol
EP1565 Safety and effectiveness of natalizumab in a real-world multiple sclerosis portuguese population Marta Sequeira
EP1566 Efficacy of Mitoxantrone in Aggressive disease in North Indian MS patients Dheeraj Khurana
EP1567 Natalizumab is an appropriate treatment choice in rapidly evolving Balo's concentric sclerosis Marc Edwards
EP1568 Real world efficacy and safety of teriflunomide in multiple sclerosis: An observational study with four years follow-up Cavit Boz
EP1569 Leptomeningeal contrast enhancement disappeared on therapy with Natalizumab in multiple sclerosis: case reports Gleb Makshakov
EP1570 A real-world, single-center, retrospective cohort analysis of alemtuzumab clinical and safety outcomes in persons with relapsing multiple sclerosis Christopher Hemond
EP1571 Alemtuzumab protects regional and global brain volumes in MS. A single subject analysis Alaleh Raji
EP1572 Long term, registry-based, prospective, post-authorization safety study evaluating adverse events of special interest in patients with highly active relapsing multiple sclerosis newly started on oral cladribine − CLARION Helmut Butzkueven
EP1573 Long-term disease stability assessed by the Expanded Disability Status Scale in patients treated with Cladribine Tablets in the CLARITY and CLARITY Extension studies Gavin Giovannoni
EP1574 One Year Prospective Follow up of Fluvastatin as an Add-on Disease Modifying Therapy in Established Relapsing Multiple Sclerosis Nazaneen Al-Ajlan
EP1575 Machine Learning Analysis of Motor Evoked Potential Time Series to Predict Disability Progression in Multiple Sclerosis Thijs Becker
EP1576 Early differentiating characteristics of clinically stable patients on low efficacy immunomodulatory treatment over long-term follow-up Tereza Hrnciarova
EP1577 Cladribine tablets: Observational evaluation of effectiveness, safety, and patient reported outcomes in suboptimally controlled patients previously taking injectable disease-modifying drugs for relapsing forms of multiple sclerosis (CLICK-MS) Augusto A. Miravalle
EP1578 Long-term clinical disease activity and adverse events in teriflunomide-treated patients following conversion to clinically definite multiple sclerosis in the TOPIC study Luwig Kappos
EP1579 Cognitive functions over the course of 5 years in multiple sclerosis patients treated with disease modifying therapies Serkan Ozakbas
EP1580 Repigmentation of vitiligo lesions in a patient treated with Teriflunomide: a case report Pablo Baena
EP1581 Alemtuzumab-related cytokine release syndrome associates with patient's age and previous disease-modifying treatments Francesca Rinaldi
EP1582 Real-World Safety and Patient Profile of Fingolimod in Relapsing-Remitting Multiple Sclerosis: How risky is Fingolimod-induced lymphopenia? Serkan Ozakbas
EP1583 Neutropenia associated with Ocrelizumab in a Multiple Sclerosis Progresive patient Virginia Meca-Lallana
EP1584 Alemtuzumab-induced thyroid disease: observational data from an Italian cohort of patients Lucia Moiola
EP1585 Natalizumab: Extended versus Standard Interval Dosing in the real world Bert Wagner
EP1586 Adverse effects of monoclonal antibodies in patients with multiple sclerosis: a real world experience Meltem Baklan
EP1587 Applying machine learning algorithms to evaluate the association between emotional expressions and therapeutic inertia among neurologists who care for people living with multiple sclerosis Gustavo Saposnik
EP1588 Effects of multi-focal intermittent theta burst stimulation on spasticity and endurance in patients with progressive multiple sclerosis Hatem Shehata
EP1589 Retrospective analysis of respository corticotropin injection use for the prevention of infusion reactions related to alemtuzumab administration in Multiple sclerosis patients Christen Kutz
EP1590 Number-needed-to-treat analysis and risk-benefit assessment of ozanimod compared with first-line disease-modifying therapies for relapsing-remitting multiple sclerosis Jinender Kumar
EP1591 Safety and tolerability data of a new brand-generic product of Teriflunomide in Iranian relapsing-remitting multiple sclerosis patients: an observational cohort study Roya Abolfazli
EP1592 A triple-blind, randomized controlled trial of Saffron in cognitive function of Multiple Sclerosis patients Amir Reza Azimi
EP1593 Year 1 Performance of adveva®, a Patient Support Programme (PSP) for patients taking MAVENCLAD® (cladribine tablets) for Highly Active Relapsing Remitting Multiple Sclerosis (RRMS) in United Kingdom (UK) Kate Morgan
EP1594 Evaluation of perception of risk and satisfaction in second-line treatments for MS Ines González-Suárez
EP1595 Improving Cognition in People with Progressive Multiple Sclerosis: A Multi-Arm, Randomized, Blinded, Sham-Controlled Trial of Cognitive Rehabilitation and Aerobic Exercise (COGEx) Anthony Feinstein
EP1596 A patient-centred evaluation of thermal resilience practices in temperature-sensitive people with Multiple Sclerosis Aikaterini Christogianni
EP1597 High-resolution whole-body mapping of warm and cold thermosensitivity in people with multiple sclerosis Aikaterini Christogianni
EP1598 Association between fatigue and upper extremity function in persons with multiple sclerosis Asiye Tuba Özdoğar
EP1599 Assessment of the effectiveness of the Exoatlet exoskeleton for the rehabilitation of the patients with multiple sclerosis Victoria Lizhdvoy
EP1600 Effect of obesity on walking and balance control in people with multiple sclerosis Turhan Kahraman
EP1601 Fatigue Relief in Multiple Sclerosis (FaReMuS): a single-center, cross over, double blinded and sham controlled study in anodal bilateral primary somatosensory areas transcranial direct current stimulation in Multiple Sclerosis Elvira Sbragia
EP1602 Investigation of long-term potentiation- and depression-induced tau phosphorylation in rats with starch based sugar Yeliz Tasci
EP1603 Effect of endurance training on serum brain-derived neurotrophic factor (BDNF) response in multiple sclerosis Seyed Massood Nabavi